Luisa M Villar Selected Research

Oligoclonal Bands

10/2021	Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability.
1/2020	New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab.
1/2018	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome.
1/2016	Intrathecal lipid-specific oligoclonal IgM synthesis associates with retinal axonal loss in multiple sclerosis.
4/2015	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes.
10/2014	Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation.
8/2014	Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis.
6/2013	Multiple sclerosis: Oligoclonal bands--a useful tool to avoid MS misdiagnosis.
1/2012	Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes.
6/2011	Increased peripheral blood CD5+ B cells predict earlier conversion to MS in high-risk clinically isolated syndromes.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Luisa M Villar Research Topics

Disease

35	Multiple Sclerosis 11/2021 - 02/2003
3	Chronic Progressive Multiple Sclerosis 01/2022 - 08/2014
3	Progressive Multifocal Leukoencephalopathy 03/2019 - 10/2005
2	Inflammation (Inflammations) 01/2022 - 08/2014
2	Disease Progression 11/2021 - 08/2014
2	Ganglion Cysts (Ganglion) 10/2021 - 01/2016
2	Rheumatoid Arthritis 01/2021 - 01/2020
2	Neuroinflammatory Diseases 01/2020 - 10/2014
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2020 - 10/2018
2	Demyelinating Diseases (Demyelinating Disease) 01/2012 - 01/2005
1	Optic Neuritis (Retrobulbar Neuritis) 10/2021
1	Lymphopenia (Lymphocytopenia) 03/2019
1	Nervous System Diseases (Neurological Disorders) 06/2017
1	Opportunistic Infections (Opportunistic Infection) 03/2015
1	Multiple Myeloma 03/2014
1	Monoclonal Gammopathy of Undetermined Significance 03/2014
1	Atrophy 01/2012
1	Motor Neuron Disease (Primary Lateral Sclerosis) 04/2005
1	Central Nervous System Infections (Central Nervous System Infection) 04/2005

Drug/Important Bio-Agent (IBA)

14	Oligoclonal BandsIBA 10/2021 - 01/2005
11	Biomarkers (Surrogate Marker)IBA 11/2021 - 04/2013
6	Immunoglobulin M (IgM)IBA 10/2021 - 02/2003
6	LipidsIBA 10/2021 - 10/2010
4	ChitinasesIBA 11/2021 - 04/2015
4	Proteins (Proteins, Gene)FDA Link 11/2021 - 01/2020
4	AntibodiesIBA 01/2021 - 06/2012
4	Natalizumab (Tysabri)FDA Link 01/2020 - 10/2005
4	AntigensIBA 09/2014 - 11/2012
3	Interferon-betaIBA 10/2018 - 01/2017
3	Immunoglobulin G (IgG)IBA 06/2015 - 04/2005
2	Retinaldehyde (Retinal)IBA 10/2021 - 01/2016
2	Tumor Necrosis Factor InhibitorsIBA 01/2021 - 01/2020
2	EnzymesIBA 01/2019 - 10/2014
2	AutoantibodiesIBA 01/2016 - 09/2014
1	ocrelizumabIBA 01/2022
1	syncytinIBA 01/2021
1	Methotrexate (Mexate)FDA LinkGeneric 01/2021
1	Leucine (L-Leucine)FDA Link 01/2020
1	InflammasomesIBA 01/2020
1	LipopolysaccharidesIBA 01/2020
1	Acetates (Acetic Acid Esters)FDA Link 01/2020
1	Adenosine Triphosphate (ATP)IBA 01/2020
1	Interleukin-1beta (Interleukin 1 beta)IBA 01/2020
1	RNA (Ribonucleic Acid)IBA 01/2020
1	PyrinIBA 01/2020
1	Dimethyl FumarateIBA 03/2019
1	pyrimidineIBA 01/2019
1	teriflunomideIBA 01/2019
1	Dihydroorotate DehydrogenaseIBA 01/2019
1	Polycomb Repressive Complex 2IBA 10/2018
1	Histone MethyltransferasesIBA 10/2018
1	PlasminogenIBA 01/2016
1	Cytidine DeaminaseIBA 10/2014
1	Immunoglobulins (Immunoglobulin)IBA 03/2014
1	AutoantigensIBA 08/2013

Therapy/Procedure

5	Therapeutics 01/2020 - 04/2013
1	Biological Therapy 01/2021
1	Precision Medicine 01/2020
1	Cell- and Tissue-Based Therapy (Cell Therapy) 10/2013